You are here

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal

Authors

  • Sho Isoyama Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa, JapanDivision of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, JapanR&D Center, Zenyaku Kogyo Co Ltd, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Shigeyuki Mori Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa, JapanR&D Center, Zenyaku Kogyo Co Ltd, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Daisuke Sugiyama Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan PubMed articlesGoogle scholar articles
  • Yasuhiro Kojima Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan PubMed articlesGoogle scholar articles
  • Yasuko Tada Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa, Japan PubMed articlesGoogle scholar articles
  • Kohei Shitara Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan PubMed articlesGoogle scholar articles
  • Kunihiko Hinohara Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan PubMed articlesGoogle scholar articles
  • Shingo Dan Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Hiroyoshi Nishikawa Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa, JapanDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan PubMed articlesGoogle scholar articles

Citation

Isoyama S, Mori S, Sugiyama D, et al
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
Journal for ImmunoTherapy of Cancer 2021;9:e002279. doi: 10.1136/jitc-2020-002279
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.